Spots Global Cancer Trial Database for Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus
Official Title: Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus
Study ID: NCT02168426
Study Description
Brief Summary: The purpose of the study is to evaluate the efficacy of Seprafilm and guardix in reducing the incidence of bowel obstruction and to evaluate the incidence of all serious adverse events (SAEs) associated with the use of Seprafilm and guardix occurring within 30 days postoperatively.
Detailed Description:
Keywords
Eligibility
Minimum Age: 25 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Won-Suk Lee, Incheon, , Korea, Republic of
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
